Pain After Root Canal Obturation With Sealer Containing or Not 1% Enoxolone

Sponsor
ACTEON Group (Industry)
Overall Status
Completed
CT.gov ID
NCT03874949
Collaborator
Slb Pharma (Other)
95
1
2
4.6
20.7

Study Details

Study Description

Brief Summary

This study aims to assess the efficacy of a zinc oxide eugenol sealer containing Enoxolone, a non-steroidal anti inflammatory drug (NSAID) on the pain relief after endodontic treatment.

The study design is a multicenter, doubled blinded randomized controlled trial. The comparator is the equivalent zinc oxide eugenol sealer without NSAID (allocation ratio is 1:1). The conventional endodontic treatment, using gutta percha and sealer, is done. Patients assess their pain for 7 days after permanent root obturation.

Condition or Disease Intervention/Treatment Phase
  • Device: SEALITE Regular
  • Device: SEALITE Ultra
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
95 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Subject will be randomized in a 1:1 allocation ratio between the two treatment groups.Subject will be randomized in a 1:1 allocation ratio between the two treatment groups.
Masking:
Double (Participant, Investigator)
Primary Purpose:
Treatment
Official Title:
Comparison of Postoperative Pain After Root Canal Obturation With Sealer Containing or Not 1% Enoxolone: a Randomized Clinical Trial
Actual Study Start Date :
Apr 2, 2019
Actual Primary Completion Date :
Aug 20, 2019
Actual Study Completion Date :
Aug 20, 2019

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: SEALITE Regular

zinc oxide eugenol sealer

Device: SEALITE Regular
Patients are treated with SEALITE Regular sealer (zinc oxide eugenol sealer). The SEALITE Regular powder is mixed with SEALITE Liquid according to the manufacturer instructions and added to gutta percha in the root canal for permanent obturation. The apical obturation is assessed by a postoperative radiographic control.

Experimental: SEALITE Ultra

zinc oxide eugenol sealer containing 1% Enoxolone (NSAID)

Device: SEALITE Ultra
Patients are treated with SEALITE Ultra sealer (zinc oxide eugenol sealer containing 1% Enoxolone). The SEALITE Ultra powder is mixed with SEALITE Liquid according to the manufacturer instructions and added to gutta percha in the root canal for permanent obturation. The apical obturation is assessed by a postoperative radiographic control.

Outcome Measures

Primary Outcome Measures

  1. Postoperative pain [24 hours]

    To assess the efficacy of Enoxolone contained in the SEALITE Ultra formula compared to the SEALITE Regular formula, the pain is assessed by patients on a diary using a Visual Analogue Scale (VAS : 0-100 mm) 24 hours after the root canal obturation.

Secondary Outcome Measures

  1. Pain response profil [0 hour, 6 hours, 12 hours, 24 hours, Day 2, Day 3, Day 7]

    Patients reporte their pain in a diary at different times after endodontic treatment using a VAS : T0 (at the end of the surgery), 6h post-op, 12h, 24h, Day 2, Day 3, Day 7, and at any other time if necessary. The maximum pain felt is compared between the 2 groups.

  2. Use of oral pain treatment [7 days]

    Patients reporte the consumption of analgesic treatment in a diary. The proportion of patients who took oral pain medication and the treatment categories are compared between the 2 groups.

  3. Adverse events [7 days]

    Adverse events reported by patients on a diary from Day 0 to Day 7 and clinically observed by the dental surgeon will assess the safety and tolerability of sealers and endodontic procedures.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 70 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • male or female aged from 18 to 70 years,

  • patient requiring root canal treatment on permanent mature teeth (single rooted teeth, premolar or molar),

  • Informed consent signed,

  • Patient with social protection.

Exclusion Criteria:
  • root canal retreatment,

  • root canal treatment on an immature tooth,

  • calcified root canal assessed radiographically,

  • Patient with one or more documented contraindication to endodontic treatment,

  • Patient who takes regular analgesic or anti-inflammatory therapy for another pathology,

  • Known allergy to NSAID or to one component of the sealer formula,

  • Participation to another clinical trial at the same time,

  • known pregnancy or lactation,

  • Patients with legal protection.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Cabinet dentaire Rennes France 35000

Sponsors and Collaborators

  • ACTEON Group
  • Slb Pharma

Investigators

  • Principal Investigator: Hugues Colombel, MD, Private dental practice

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
ACTEON Group
ClinicalTrials.gov Identifier:
NCT03874949
Other Study ID Numbers:
  • SEAU
First Posted:
Mar 14, 2019
Last Update Posted:
Sep 4, 2019
Last Verified:
Sep 1, 2019
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No

Study Results

No Results Posted as of Sep 4, 2019